BI lung cancer trial meets PFS primary endpoint

Monday 4 June 2012

Boehringer Ingelheim Pharmaceuticals Inc said that a Phase 3 trial of its tyrosine kinase inhibitor, afatinib, in patients with non-small lung cancer reached its primary endpoint of progression free survival. Data are being presented at Asco on 4 June.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States